ArticleHaematologica2019

Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with

Akiko Uchida et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.